Search

• GSK receives EU marketing authorisation for Incruse (umeclidinium) for the treatment of COPD

  Media

  GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse®

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-eu-marketing-authorisation-for-incruse-umeclidinium-for-the-treatment-of-copd/

  First published: 28 April 2014

• ViiV Healthcare announces start of phase III study evaluating long-acting cabotegravir for HIV prevention

  Media

  First injectable to be studied for efficacy in pre-exposure prophylaxis

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention/

  First published: 20 December 2016

• GSK leads Access to Medicine Index 2016

  Media

  GSK has today been ranked first in the Access to Medicine Index for the fifth consecutive time.

  https://www.gsk.com/en-gb/media/press-releases/gsk-leads-access-to-medicine-index-2016/

  First published: 14 November 2016

• GSK and Adaptimmune expand strategic immunotherapy collaboration

  Media

  GSK and Adaptimmune Therapeutics have expanded the terms of their strategic collaboration agreement

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-adaptimmune-expand-strategic-immunotherapy-collaboration/

  First published: 02 February 2016

• GSK receives approval for Incruse™ Ellipta® (umeclidinium) in the US for the treatment of COPD

  Media

  GSK announced that the FDA has approved umeclidinium as treatment of airflow obstruction in patients with COPD.

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-approval-for-incruse-ellipta-umeclidinium-in-the-us-for-the-treatment-of-copd/

  First published: 30 April 2014

• GSK and Genmab receive FDA approval for Arzerra® (ofatumumab)

  Media

  GSK and Genmab announced today that CHMP of the European Medicines Agency (EMA) has issued a positive opinion recommending a variation.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-fda-approval-for-arzerra-ofatumumab/

  First published: 23 May 2014

• GSK and Genmab announce positive interim result for phase III study of ofatumumab as maintenance therapy for relapsed CLL

  Media

  GSK & GEN announced that an Independent Data Monitoring Committee (IDMC) interim analysis of a phase III study, PROLONG (OMB 112517)

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-announce-positive-interim-result-for-phase-iii-study-of-ofatumumab-as-maintenance-therapy-for-relapsed-cll/

  First published: 31 July 2014

• GSK and Genmab receive FDA approval for Arzerra

  Media

  GSK & GEN announced today that the FDA has approved a sBLA for Arzerra® (ofatumumab) for CLL

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-fda-approval-for-arzerra/

  First published: 17 April 2014

• GSK's Promacta® (eltrombopag) receives FDA approval of an additional indication

  Media

  New first-in-class treatment option for this previously treated SAA patient population

  https://www.gsk.com/en-gb/media/press-releases/gsks-promacta-eltrombopag-receives-fda-approval-of-an-additional-indication/

  First published: 26 August 2014

• GSK submits regulatory application for chlorhexidine gel for the prevention of umbilical cord infections in newborn babies

  Media

  GSK announced it's submitted an application to EMA for antiseptic chlorhexidine gel for the prevention omphalitis in newborn babies.

  https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-for-chlorhexidine-gel-for-the-prevention-of-umbilical-cord-infections-in-newborn-babies/

  First published: 12 October 2015